Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Univariable analysis of potential the risk factors for predicting the prognosis of NMOSD

From: Free thyroxine level is associated with both relapse rate and poor neurofunction in first-attack Neuromyelitis Optica Spectrum Disorder (NMOSD) patients

FactorStatistical valueRelapseFinal EDSS
HR (95% CI)P valueβ (95% CI)P value
Male sex - no. (%)27 (24.77)0.71 (0.35, 1.42)0.3310.06 (−0.72, 0.83)0.887
Age (years)42.21 ± 15.451.00 (0.99, 1.02)0.6990.00 (− 0.02, 0.03)0.754
Hypertension - no. (%)13 (11.93)2.76 (1.37, 5.56)0.004*−0.17 (−1.20, 0.87)0.754
Diabetes - no. (%)7 (6.42)1.64 (0.65, 4.14)0.293−0.15 (− 1.51, 1.21)0.830
Initial EDSS4.89 ± 1.800.95 (0.82, 1.11)0.5360.36 (0.19, 0.53)< 0.001*
Vision (EDSS of vision)1.71 ± 1.981.05 (0.91, 1.21)0.4910.01 (−0.15, 0.18)0.866
Anti-AQP-4 antibody - no. (%)
 Not tested30 (27.52)1.0   
 Negative30 (27.52)0.72 (0.33, 1.57)0.4130.03 (−0.86, 0.92)0.942
 Positive49 (44.95)1.20 (0.64, 2.23)0.5690.69 (−0.11, 1.49)0.094
Autoimmune - no. (%)5 (4.59)1.98 (0.61, 6.41)0.2560.56 (−1.04, 2.15)0.495
Corticosteroid - no. (%)95 (87.16)1.06 (0.51, 2.21)0.8810.53 (−0.46, 1.52)0.299
IVIG - no. (%)5 (4.59)0.91 (0.22, 3.73)0.8911.29 (−0.29, 2.87)0.112
Immunosuppressant - no. (%)26 (23.85)1.41 (0.76, 2.62)0.272−0.42 (−1.20, 0.36)0.295
Rehabilitation - no. (%)23 (21.1)1.24 (0.65, 2.37)0.5100.19 (−0.63, 1.01)0.653
FT3 - pmol/L4.55 ± 0.830.96 (0.69, 1.34)0.8270.20 (−0.21, 0.60)0.343
FT4 - pmol/L11.46 ± 2.491.16 (1.04, 1.28)0.006*0.19 (0.06, 0.32)0.006*
TSH -μIU/mL3.21 ± 9.390.98 (0.93, 1.03)0.419−0.02 (−0.06, 0.01)0.216
  1. no. Number, EDSS Expanded Disability Status Scale, IVIG Intravenous immunoglobulin, FT3 Free triiodothyronine; FT4 Free thyroxine, TSH Thyroid stimulating hormone
  2. *P < 0.05 indicates a significant difference between the two groups